Home › Cancro dello stomaco › New York › New York City
Studi clinici su Cancro dello stomaco a New York City, NY
31 studi su Cancro dello stomaco cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
In reclutamentoFase 2
- Memorial Sloan Kettering Hospital, New York
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
In reclutamentoFase 2/3
- Memorial Sloan Kettering Cancer Center, New York
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
In reclutamentoFase 3
- Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
In reclutamentoFase 2/3
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Rockefeller Outpatient Pavilion (53rd Street), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
In reclutamentoFase 2
- Research Site, New York
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
In reclutamentoFase 1
- New York University (NYU) Langone Medical Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
In reclutamentoFase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
In reclutamentoFase 3
- Icahn School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of 2141-V11 in People With Esophageal, Gastric, or Gastroesophageal Junction Adenocarcinoma
In reclutamentoFase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
In reclutamentoFase 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
A Phase 1/1b Study of IAM1363 in HER2 Cancers
In reclutamentoFase 1
- Icahn School of Medicine at Mount Sinai, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
In reclutamentoFase 1/2
- Memorial Sloan Kettering Hospital, New York
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
In reclutamentoFase 1
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
In reclutamentoFase 3
- Memorial Sloan Kettering Cancer Center - MAIN, New York
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
In reclutamentoFase 1/2
- Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
In reclutamentoFase 1
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
In reclutamentoFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
In reclutamentoFase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
- Columbia University Irving Medical Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
In reclutamentoFase 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
In reclutamentoFase 2
- Research Site, New York
Brodalumab in the Treatment of Immune-Related Adverse Events
In reclutamentoFase 1
- Columbia University Irving Medical Center, New York
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
In reclutamentoFase 1/2
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study Collecting Health Information to Understand and Prevent Gastric Cancer
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
Avutometinib and Defactinib in Diffuse Gastric Cancer
In reclutamentoFase 2
- Columbia University Irving Medical Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, New York
Comprehensive Outcomes for After Cancer Health
In reclutamentoVolontari sani benvenuti
- Memorial Sloan Kettering Cancer Center, New York
Studi su Cancro dello stomaco in altre città
- Houston, TX42 studi
- Boston, MA32 studi
- Nashville, TN28 studi
- Baldwin Park, CA22 studi
- Los Angeles, CA22 studi
- Arlington, VA20 studi
- Dallas, TX19 studi
- San Antonio, TX19 studi
- Grand Rapids, MI18 studi
- St. Louis, MO18 studi
- Washington, DC16 studi
- Chicago, IL16 studi
Altri studi a New York City
- Cancro al seno136 studi
- Cancro del polmone non a piccole cellule121 studi
- Cancro (tutti i tipi)109 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale78 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Mieloma multiplo60 studi
- Cancro pancreatico60 studi
- Cancro dell'endometrio52 studi
- Leucemia mieloide acuta51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.